SCHEMBL6747735

SCHEMBL6747735

O=C1[C@H]2CC=CC[C@H]2C(=O)N1Cc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 1.00
CA12 O43570 1/20 0.62
CA1 P00915 1/20 0.62
CA2 P00918 1/20 0.62
CA9 Q16790 1/20 0.62
KMT2A Q03164 2/20 0.59
MEN1 O00255 1/20 0.59
TDP1 Q9NUW8 2/20 0.58
TP53 P04637 1/20 0.58
USP2 O75604 1/20 0.56
HSD17B10 Q99714 1/20 0.56
TSHR P16473 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
ACHE P22303 1/20 0.54
F2 P00734 1/20 0.53
PLG P00747 1/20 0.53
ELANE P08246 1/20 0.53
CTSG P08311 1/20 0.53
CMA1 P23946 1/20 0.53
CTRC Q99895 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6747736 1.00 ALDH1A1 (1.00) ALDH1A1CA12CA1CA2CA9
SCHEMBL12119582 0.87 ALDH1A1 (0.77) ALDH1A1CA12CA1CA2CA9
SCHEMBL1023519 0.85 ALDH1A1 (0.73) ALDH1A1KMT2AMEN1USP2TSHR
SCHEMBL13783795 0.85 ALDH1A1 (0.73) ALDH1A1KMT2AMEN1USP2TSHR
SCHEMBL12372537 0.85 ALDH1A1 (0.73) ALDH1A1KMT2AMEN1USP2TSHR
SCHEMBL7382903 0.82 ALDH1A1 (0.70) ALDH1A1CA1CA2CA9KMT2A
SCHEMBL7382899 0.82 ALDH1A1 (0.70) ALDH1A1CA1CA2CA9KMT2A
SCHEMBL3236740 0.81 ALDH1A1 (0.69) ALDH1A1KMT2AMEN1TSHRSMN1; SMN2
SCHEMBL8383162 0.81 ALDH1A1 (1.00) ALDH1A1KMT2AMEN1USP2TSHR
SCHEMBL7829113 0.81 ALDH1A1 (0.93) ALDH1A1KMT2AMEN1USP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092737-A1 Benzopiperidine derivatives EISAI CO., LTD. 2004-05-13 US disclosed
US-6518423-B1 These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and EISAI CO., LTD. (JP) 2003-02-11 US disclosed
EP-0934941-A1 BENZOPIPERIDINE DERIVATIVES Eisai Co., Ltd. (JP) 1999-08-11 EP disclosed
US-5409929-A Treating psychosis, dyskinesia THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1995-04-25 US disclosed
EP-0626947-A1 HYDROISOINDOLINES AND HYDROISOQUINOLINES AS PSYCHOTROPIC DRUGS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1994-12-07 EP disclosed
WO-1993016047-A1 HYDROISOINDOLINES AND HYDROISOQUINOLINES AS PSYCHOTROPIC DRUGS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-08-19 WO disclosed
US-5216018-A Antidyskinetic agents DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092737-A1 Benzopiperidine derivatives HLA-DRB1, HRH1, HRH2 ALDH1A1 145/4885CA12 4489/4885CA1 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.